Drug Profile
Delavirdine
Alternative Names: Delavirdine mesylate; Rescriptor; U 90152T; U-90152-SLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Daiichi Sankyo Company; Pfizer
- Class Antiretrovirals; Indoles; Piperazines; Small molecules
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed HIV-1 infections
Most Recent Events
- 07 Jul 2010 Development discontinued in the European Union before 2001
- 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
- 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer